Many questions surround new Alzheimer’s treatment

March 25, 2015 12:57 AM

17 0

Though a new drug may be able to treat early stage Alzheimer’s, this may not be as good as it originally seems.

Biogen, a Cambridge, Massachusetts biotech company is behind the drug (aducanumab) that acts as a monoclonal antibody, NBC News reports. The drug has shown impressive results in early tests on those with early stage Alzheimer’s disease, and it has also significantly reduced the amyloid plaque buildu...

Read more

To category page